Ever Pharma Polandsp. z o.o.

EVER Pharma Gained EU-Approval of Testosterone Enantate

EVER Pharma, a fully integrated specialty pharmaceuticals company, is pleased toannounce the approval of Testosterone Enantate in the European Union for thetreatment of male hypogonadism. This condition, characterized by insufficienttestosterone production, affecting up to 10% of men globally and 40% of men aged 451. Male hypogonadism can significantly impact a person’s quality of life, manifesting … Continued

EVER Pharma gained EU-Approval for Advanced Cancer Treatment

EVER Pharma, a fully integrated specialty pharmaceuticals company, announced the approval of Eribulin in the European Union. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma1. Despite advances in early detection and treatment, metastatic breast cancer remains untreatable, typically resulting in a median overall survival of approximately 2-3 … Continued

EVER Pharma Announces Approval of Testosterone Undecanoate in the EU

EVER Pharma, a fully integrated specialty pharmaceuticals company, has announced the approval of Testosterone Undecanoate in the European Union for the treatment of male hypogonadism. This therapy, an intramuscular injection with a unique depot formulation, has been shown to effectively treat the symptoms of hypogonadism in men with confirmed testosterone deficiency1. Male hypogonadism is a … Continued

EVER Pharma Expands Operations with Opening of New Manufacturing Facility in Jena, Germany

EVER Pharma is proud to announce the official opening of its new manufacturing facility in Jena, Germany, marking a significant milestone in the company’s strategic development as a vertically integrated leader in injectables. EVER Pharma has had an active presence in Jena since 2011, and this latest expansion with an overall investment of €240m underscores … Continued

EVER Pharma gains EU Marketing Authorization for Trabectedin

EVER Pharma is pleased to announce the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer1. Soft tissue sarcoma (STS) and ovarian cancer are rare forms of cancer affecting in total around 150,000 patients in the European Union. Trabectedin is recommended for treating advanced STS2. It is also an important treatment option for patients with relapsed ovarian … Continued

EVER Pharma receives EU approval for a liquid ready to use Bortezomib formulation

EVER Pharma is pleased to announce EU-wide approval of Bortezomib for the treatment of patients with multiple myeloma and mantle cell lymphoma1. Bortezomib EVER Pharma is a liquid ready to use formulation that offers several advantages over the many powder formulations available on the market. It does not require reconstitution prior to preparation, allowing the safe … Continued